It's an acquisition that aims at forming one of the US's largest oncology trial networks
Paradigm Health is set to acquire Flatiron Health’s Clinical Research Business, a move that unites the industry’s largest tech-enabled US oncology research network with a powerful suite of clinical research tools.
The deal also launches a multi-year collaboration aimed at expanding trial access and modernizing how studies are conducted across the country.
With the acquisition, Paradigm Health will instantly scale its reach to more than 25 academic medical centers and health systems, alongside nearly 100 community oncology practices nationwide—touching over 2.4 million patients.
The companies plan to integrate Flatiron’s long-established research solutions and site network with Paradigm’s AI-driven, end-to-end platform, broadening the availability of clinical trials without requiring costly new infrastructure.
“Clinical research must reflect the populations that new therapies are intended to serve,” said Kent Thoelke, Paradigm Health, CEO. “By combining Paradigm Health’s AI-powered platform with Flatiron’s proven clinical research infrastructure and research network, we are taking a major step towards our goal of accelerating our impact in the U.S. so that more trials can happen where patients actually receive care.”
The partnership underscores a strategic effort to expand U.S. clinical research capacity and bring studies directly into the communities where patients live.
Flatiron CEO Nathan Hubbard said the deal strengthens a shared mission to streamline research and speed new treatments to market. “This partnership brings together the strengths of both organizations,” he said. “By combining Paradigm Health’s AI-powered trial infrastructure with Flatiron’s trusted network and support across academic and community oncology sites, we’re building a stronger, more connected ecosystem for clinical research - expanding capabilities, accelerating impact and advancing our shared mission to bring new treatments to patients faster.”
As part of the long-term strategic partnership, Paradigm’s clinical trial tools will be natively integrated into Flatiron’s OncoEMR, expanding research capabilities for all OncoEMR customers as well as Flatiron’s existing research partners.
Paradigm will take on clinical research support across the network, aiming to boost trial availability in new regions and among underrepresented patient groups. The combined effort promises smoother adoption of AI-enabled capabilities and deeper investment in technologies that streamline trial design and execution.
The acquisition also strengthens Paradigm’s ties with major biopharma sponsors. The unified network will serve 15 of the world’s 20 largest biopharma companies and expand capacity for pragmatic, Phase IV studies embedded directly in routine care—accelerating real-world evidence generation after drug approval.